Publicaciones en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (30)

2024

  1. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

  2. Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial

    Clinical Infectious Diseases, Vol. 78, Núm. 3, pp. 702-710

2023

  1. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change

    Journal of Acquired Immune Deficiency Syndromes, Vol. 93, Núm. 1, pp. 42-46

  2. DESTINY-Breast03 trial: some questions remain – Authors' reply

    The Lancet

  3. First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

    Journal of the Pediatric Infectious Diseases Society, Vol. 12, Núm. 11, pp. 581-585

  4. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

    European Journal of Cancer, Vol. 178, pp. 23-33

  5. Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

    Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e93-e103

  6. PSMA PET/CT imaging for biochemical recurrence of prostate cancer after radiotherapy: is it necessary to review the Phoenix criteria?

    Clinical and Translational Imaging, Vol. 11, Núm. 3, pp. 241-254

  7. TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease

    Nature Cardiovascular Research, Vol. 2, Núm. 2, pp. 144-158

  8. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10371, pp. 105-117

2022

  1. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

    Therapeutic Advances in Medical Oncology, Vol. 14

  2. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139

  3. Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial

    Trials, Vol. 23, Núm. 1

  4. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

    Cancers, Vol. 14, Núm. 20

  5. Miniseries 2-Septal and paraseptal accessory pathways-Part I: The anatomic basis for the understanding of para-Hisian accessory atrioventricular pathways

    Europace, Vol. 24, Núm. 4, pp. 639-649

  6. Miniseries 2-Septal and paraseptal accessory pathways-Part II: Para-Hisian accessory pathways-so-called anteroseptal pathways revisited

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 24, Núm. 4, pp. 650-661

  7. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

    npj Breast Cancer, Vol. 8, Núm. 1

  8. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

    npj Breast Cancer, Vol. 8, Núm. 1

  9. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 12, pp. 1142-1154

2021

  1. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

    Future Oncology, Vol. 17, Núm. 30, pp. 3911-3924